Canadian Peptide Research Society

Circles enable healthcare providers to develop, own, and benefit from genuine real-world evidence, not clinically irrelevant reimbursement codes.  Circles prospectively define and structure RWE arising from the everyday practice of medicine.  The resulting Circle Datasets represent significant clinical, scientific, and financial value.  They can support regulatory submissions, product development, clinical decision-making, value-based care, and AI model training.

While randomized controlled trials (RCTs) remain the research “gold standard,” they are costly, complex, slow, and often inaccessible.  Publication bias and limited scope further reduce their usefulness.  Circles offer an efficient and low-cost approach to generating clinically relevant and trustworthy data, while maintaining most of the rigor of RCTs.

Circles offerclinical, financial, and reputational benefits:

1. Allow ownership and monetization of datasets, creating new income streams and development of intellectual property.
2. Support clinical decision-making and evidence-based standards of care.
3. Enable participation in meaningful research without disrupting normal clinical flow.
4. Provide fresh, clinically relevant datasets for publications, presentations, and educational materials.
5. Enhance training, patient education, and payer relations (including reimbursement and value-based care requirements).
6. Create opportunities to collaborate with other participants.

Healthcare data entry is of course prevalent.  That data collection focuses on reimbursement, revenue cycle management, and similar operational matters.  Those platforms are costly and delivers little real clinical let alone financial benefits.  Meanwhile, the healthcare data analytics market is worth over $70 billion and growing rapidly.  Others are benefiting significantly from providers’ clinical data entry, but not the providers themselves.  Moreover, healthcare is shifting from fee-for-service to value-based care, and most current data systems are not designed to meet those requirements.

Even strong research programs face challenges:

1. High staffing and systems costs with declining grant availability.
2. Difficulty publishing impactful results in an oversaturated information environment.
3. Long timelines to develop and publish studies.
4. Gaps, unverifiable entries, and potential bias in published datasets.
5. Rare publication of “negative” results, reducing credibility.
6. Limited ability to translate findings into everyday clinical care.

Circles programs provides a low-cost, efficient, and scalable method for generating clinically meaningful research data, while directly supporting real-world clinical translation.

Yes.  See Return On Investment, below.

Attributes are unique identifiers prospectively and retrospectively assigned to each Observational Protocol, Circle, and Case by the Circles platform.  Together with Datapoints, they underpin the clinical, scientific, and financial value of Circle Datasets.  Examples of Attributes include Anatomical Area, Disease/Pathology, Treatment Protocol, Assessment, Medical Codes (CPT, ICD, HCPCS, etc.), Circle, Principal Investigator, and Investigator.

A Case is a single Treatment Protocol delivered to a single Patient by any number of Investigators over any time period, and includes patient reported outcomes.  All Case Datapoints are thus tightly correlated to OP and Circle Attributes.  Cases are the foundational elements of each Circle Dataset.

A Circle is defined by the Investigators creating Cases against a single Observational Protocol.  Those Investigators may be located within or across institutional and national borders.

A Circle Dataset is any clinically significant set of Cases sharing one or more common Attributes.

A Circle Hour is a secure video conference during which Investigators review Circles data trends, exchange best practices, and propose new OPs.  A Circle Hour is typically co-moderated by a PI.

A Datapoint is an Answer to an OP Question collected in the context of a Case.  Each Datapoint is thus associated with all Attributes assigned to that Case.

An Investigator is usually a clinician, but may also be a researcher or other healthcare professional, participating in a Circle.

An Investigator Entity is a legal entity (from a sole practitioner to a large medical center) participating in a Circle.  The Investigator Entity executes the Participation Agreement and determines how its share of Circle Dataset revenue will be distributed among affiliated Investigators.

Circle Datasets licensing will be the most common form of monetization.  Potential licensees include payers, product manufacturers, AI models, research centers, value-based care groups, SDOH entities (e.g., Managed Medicaid Organizations), and RWE data aggregators.  Note that a single Circle Dataset is likely to have several licensees.  Moreover, because each Circle Dataset is longitudinal, it automatically becomes more valuable as it continues to accumulate correlated data.

Analogous to an RCT study protocol, each OP is defined by all of its Attributes.  OPs comprise Surveys for patients, clinicians, and third parties (e.g., labs).  Each OP is designed for efficient secure clinical data entry on any device.  An OP is subdivided into separate Surveys, each built to be completed in no more than thirty seconds.

An optional peer review panel of clinical/scientific experts who evaluate a proposed OP.  It may be established in lieu of or in conjunction with an IRB.

A PI assists RegenMed and any Sponsor with the recruitment and support of Investigators for a given Circle.  When relevant, a PI also prepares the OP for review by an IRB or designated Observational Protocol Review Committee.  A PI also usually but not necessarily also serves as an Investigator.   When more than one Investigator Entity is involved in a Circle, there is usually a PI for each such Entity.

A Sponsor may be a medical society, hospital, or other RegenMed partner.  In many such instances, the Sponsor will have its own rules for participation, which will be described separately in this section.

Data can be accessed at any time from any device, with the option to download raw data files without additional charge.

Once approved, OPs are available to a wide range of credentialed healthcare providers, from academic centers to independent practitioners.  Approval criteria are set by the Sponsor, if any, and/or RegenMed.  Typically, those criteria are principally based on Investigator professional credentials.

Subject to any restrictions put in place by a Sponsor or Investigator Entity, Investigators can download any contributed Circles data at any time prior to discontinuing Circle participation.

Minimal. The Circles platform is designed for seamless integration into clinical workflows, requiring no extra staff or systems.

Final OP Questions are determined by the PI and, where applicable an IRB and/or a Sponsor’s Observational Protocol Review Committee.  Investigators may add their own Questions to an approved OP, but should avoid excessive additions to maintain high compliance and data quality.  Separately from the Circles covered on this page, an Investigator can always initiate his/her own Circle.

Yes.  Any approved healthcare professional can join any number of Circles, or start his/her own.

For an Investigator Entity, one-time customization/setup fee for the Circle: $4,250.

Monthly Subscription per Circle Platform User: $35.

Per longitudinal Case: $5

Clinical/Scientific Support: $150/hour

Technical Support: $100/hour

Full Product Pricing and Terms can be found here.

Typically, through Licenses.  Development of intellectual property supported by Circle Datasets is another monetization avenue.‍

RegenMed receives 15% of net License or other monetization revenues.  The remaining 85% is allocated to the Sponsor (if any), Investigator Entity (if any) and Investigators according to the terms of the relevant Circles Participation Agreement.  The Circles platform tracks the source of each Datapoint, and is therefore able to allocate net monetization amounts to Investigator Entities and/or Investigators according to their Datapoint contributions to the licensed Circle Dataset.